intermittent use of high-dose ICS (

intermittent use of high-dose ICS (1,600–3,200 μg/day BDP or BUD) as evidenced by a reduction in the severity of symptoms. There was also a trend for reduced requirements of oral corticosteroids. More recently, a controlled, randomised, double-blind clinical trial of 750 μg FP versus placebo twice daily in 129 children who were 1–6 year of age with recurrent virus-induced wheezing showed a reduction in the use of rescue oral corticosteroids in the FP-treated patients [24]. However, treatment with FP was associated with a smaller gain in height and weight. Among preschool children, no benefit was shown for continuous low-dose ICS treatment (400 μg/day BUD) with respect to a reduction in the number or the severity of wheezing episodes [75]. Finally, a double-blind, placebo-controlled, randomised interventional study, primarily designed to assess whether or not treatment with intermittent courses of inhaled budesonide (400 μg/day) versus placebo for 2 weeks during wheezing episodes could delay progression to persistent wheezing, did not show any benefit of ICS during the first 3 years of life [11

ผลลัพธ์ (อังกฤษ) 3:

Intermittent use of high-dose ICS (1 600 - 3, 200), thermal g / day BDP or BUD) as evidenced by a reduction in the severity of, symptoms. There was also a trend for reduced requirements of oral corticosteroids. More recently a controlled randomised,,,Double-blind clinical trial of 750 as thermal g FP versus placebo twice daily in 129 children who were 1 - 6 year of age with recurrent. " Virus-induced wheezing showed a reduction in the use of rescue oral corticosteroids in the FP-treated patients []. However, 24, Treatment with FP was associated with a smaller gain in height and weight Among, preschool children.No benefit was shown for continuous low-dose ICS treatment (400 as thermal g / day BUD) with respect to a reduction in the number or. The severity of wheezing episodes []. Finally a 75, double - blind placebo-controlled randomised interventional study,,,Primarily designed to assess whether or not treatment with intermittent courses of inhaled budesonide (400 as thermal g / day versus.) Placebo for 2) weeks during wheezing episodes could delay progression to persistent wheezing did not, show any benefit of. ICS during the first 3 years of life [11. "